Background: The Hancock II bioprosthesis has been used for heart valve replacement since 1982 in our institution. We previously reported its clinical performance at 8 years and at 10 years. This is a progress report on its performance at 12 years.
Methods: From 1982 to 1994 the Hancock II bioprosthesis was used for aortic valve replacement (AVR) in 723 patients and for mitral valve replacement (MVR) in 328 patients. The mean age of the patients was 65 years for both groups. Coronary artery disease was present in 42% of patients who had AVR and 45% of patients who had MVR. Patients have been followed up prospectively at annual intervals; the mean follow-up was 68+/-40 months for AVR and 66+/-43 months for MVR; it was 99% complete.
Results: There were 36 (5%) operative and 159 late deaths in the AVR group, and 26 (8%) operative and 92 late deaths in the MVR. The actuarial survival at 12 years was 54%+/-4% for AVR and 42%+/-5% for MVR. Age greater than 65 years and coronary artery disease had a profound effect on late survival. At 12 years the freedom from thromboembolism was 86%+/-2% for AVR and 90% +/-2% for MVR; from endocarditis, 95%+/-1% for both groups; from primary tissue failure, 94%+/-2% for AVR and 82%+/-5% for MVR; and from valve reoperation, 89% +/-3% for AVR and 78%+/-5% for MVR. There was no primary tissue failure at 12 years in patients older than 65 years who had AVR.
Conclusions: The clinical performance of the Hancock II has been very satisfactory and this bioprosthesis appears to be more durable than its predecessors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0003-4975(98)01099-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of four aortic bioprostheses: Hancock II St Jude Trifecta Carpentier-Edwards Perimount Magna Magna Ease-mid-term results (COMPARE SAVR study).
J Thorac Dis
August 2024
CAROL-Cardiothoracic Anatomy Research Operative Lab, Department of Cardiovascular Surgery and Transplantology, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland.
Background: In the era of percutaneous aortic valve implantation, biological valves are the preferred prostheses implanted in patients undergoing surgical aortic valve replacement (sAVR). The aim was to present a real-life analysis of mid-term sAVR outcomes for the four aortic bioprostheses: the Hancock II, the Carpentier-Edwards Perimount Magna, the Carpentier-Edwards Perimount Magna Ease and the Trifecta valve.
Methods: This is a retrospective study based on data from the Polish National Cardiac Surgery Database.
Restricted cusp motion in newly implanted tricuspid bioprostheses: Incidence, predictors, and impact on survival.
J Thorac Cardiovasc Surg
May 2024
Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minn.
Article Synopsis
- - The study aimed to explore the occurrence of restricted cusp motion (RCM) during bioprosthetic tricuspid valve replacement (TVR) and its risk factors and effects on patient outcomes.
- - Out of 476 patients analyzed from 2012 to 2022, 31.5% exhibited RCM, with 13.2% having complete immobility and 18.3% showing limited movement of the valve cusp.
- - The research found that certain factors, like the type of valve used and patient-specific measurements, significantly influenced the likelihood of RCM, which was linked to a higher mortality risk, highlighting the importance of careful prosthesis selection.
The Ongoing Debate: Longevity of Biological Valves in Pulmonary Position.
Thorac Cardiovasc Surg
January 2024
Bereich Kinderherzchirurgie/Chirurgie angeborener Herzfehler, Klinik für Kinderherzmedizin und Erwachsene mit angeborenen Herzfehlern, Universitäres Herz- und Gefäßzentrum Hamburg, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
Article Synopsis
- The study investigates factors affecting the durability of biological valves used in patients with tetralogy of Fallot (ToF) over a follow-up period of nearly a decade.
- 79 patients aged 0.2 to 56.1 years underwent surgery for valve implantation, with various types of conduits being utilized.
- Results indicate that younger age, smaller valve size, and higher z-scores are linked to decreased valve longevity, emphasizing patient age as a key factor in graft lifespan.
Bioprosthetic Valve Remodeling in Nonfracturable Surgical Valves: Impact on THV Expansion and Hydrodynamic Performance.
JACC Cardiovasc Interv
July 2023
Centre for Cardiovascular Innovation, St. Paul's and Vancouver General Hospital, Vancouver, Canada; Cardiovascular Translational Laboratory, Providence Research and Centre for Heart Lung Innovation, Vancouver, Canada; Centre for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address:
Background: There are limited data on the effect of bioprosthetic valve remodeling (BVR) on transcatheter heart valve (THV) expansion and function following valve-in-valve (VIV) transcatheter aortic valve replacement (TAVR) in a nonfracturable surgical heart valve (SHV).
Objectives: This study sought to assess the impact of BVR of nonfracturable SHVs on THVs after VIV implantation.
Methods: VIV TAVR was performed using 23-mm SAPIEN3 (S3, Edwards Lifesciences) or 23/26-mm Evolut Pro (Medtronic) THVs implanted in 21/23-mm Trifecta (Abbott Structural Heart) and 21/23-mm Hancock (Medtronic) SHVs with BVR performed with a noncompliant TRUE balloon (Bard Peripheral Vascular Inc).
Valve-in-valve transcatheter transfemoral mitral valve implantation (ViV-TMVI): Characteristics and early results from a nationwide registry.
Kardiol Pol
April 2023
Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland.
Background: Valve-in-valve transcatheter transfemoral mitral valve implantation (ViV-TMVI) is an emerging treatment alternative to reoperation in high-surgical risk patients with failed mitral bioprostheses.
Aim: We aimed to describe the characteristics of ViV-TMVI and evaluate its 30-day outcomes in the Polish population.
Methods: A nationwide registry was initiated to collect data on all patients with failed mitral bioprosthesis undergoing ViV-TMVI in Poland.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!